Lynette M. Brown, MD, PhD

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Associate Professor (Clinical)
  • Divisions: Pulmonary

Academic Office Information

  • 801-507-3378
  • Intermountain Medical Center
    5121 Cottonwood Street, Room: Suite 307
    Murray, UT 84107

Education History

Type School Degree
Fellowship Johns Hopkins School of Medicine
Pulmonary Critical Care Medicine
Fellow
Residency Johns Hopkins School of Medicine
Internal Medicine
Resident
Professional Medical Johns Hopkins School of Medicine
Medicine
M.D.
Postdoctoral Fellowship University of Kansas
Pharmaceutical Chemistry
Postdoctoral Fellow
Doctoral Training University of Oklahoma Health Sciences Center
Medicinal Chemistry
Ph.D.
Undergraduate University of Oklahoma
Chemistry
B.S.

Selected Publications

Journal Article

  1. Best DH, Sumner KL, Smith BP, Damjanovich-Colmenares K, Nakayama I, Brown LM, Ha Y, Paul E, Morris A, Jama MA, Dodson MW, Bayrak-Toydemir P, Elliott CG (2016). EIF2AK4 Mutations in Patients Diagnosed with Pulmonary Arterial Hypertension.LID - S0012-3692(16)62396-6 [pii]LID - 10.1016/j.chest.2016.11.014 [doi]. (Epub ahead of print) Chest.
  2. Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk AC, Rosenzweig EB, Bayrak-Toydemir P, Mao R, Cahill BC, Tazelaar HD, Leslie KO, Hemnes AR, Robbins IM, Elliott CG (Winter 2013). EIF2AK4 Mutations in Pulmonary Capillary Hemangiomatosis. Chest, 145, 231-236.
  3. Adams DM, Stevens SM, Woller SC, Evans RS, Lloyd JF, Snow GL, Allen TL, Bledsoe JR, Brown LM, Blagev DP, Lovelace TD, Shill TL, Conner KE, Aston VT, Elliott CG (2013). Adherence to PIOPED II investigators' recommendations for computed tomography pulmonary angiography. Am J Med, 126(1), 36-42.
  4. Brown LB and Elliott CG (2012). Time to diagnosis of pulmonary arterial hypertension. Adv Pulm Hypertens, 11(2), 69-72.
  5. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG (2011). Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest, 140(1), 19-26.
  6. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ (2010). Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest, 137(6 Suppl), 85S-94S.
  7. Magarian RA, Avor K, Overacre LB, Kunchandy J, Paxton TR (1995). Synthesis and Biological Evaluation of Side Chain Derivatives of Analog II as Pure Antiestrogens and Antitumor Agents. Anticancer Drug Des, 10, 311-331.
  8. Hossain MB, van der Helm D, Schmitz FJ, Podesimo EO, Magarian RA, Meyer KL, Overacre LB, Day BW (1994). Molecular Structures and Conformational Studies of Triarylcyclopropol and Related Antiestrogens. J Med Chem, 37, 1670-1683.

Patent

  1. LM Overacre, RA Magarian (1997). Estrogen Receptor Blockers. U.S. Patent No. 5,658,951. Washington, D.C.:U.S. Patent and Trademark Office.
  2. LM Overavce, RA Magarian (1997). Estrogen Receptor Blockers. U.S. Patent No. 5,658,927. Washington, D.C.:U.S. Patent and Trademark Office.
  3. LM Overacre, RA Magarian (1997). Estrogen Receptor Blockers. U.S. Patent No. 5,658,917. Washington, D.C.:U.S. Patent and Trademark Office.